Yunsoo Kim

Array ( [id] => 19201490 [patent_doc_number] => 20240173389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => Compositions and Methods For Reducing Immune Intolerance [patent_app_type] => utility [patent_app_number] => 18/279612 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18279612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20293930 [patent_doc_number] => 20250319173 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-16 [patent_title] => LENTIVIRAL VECTORS TARGETING ANTIGENS TO MHC-II PATHWAY AND INDUCING PROTECTIVE CD8+ AND CD4+ T-CELL IMMUNITY IN A HOST [patent_app_type] => utility [patent_app_number] => 18/549286 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18549286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20356188 [patent_doc_number] => 12472167 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity [patent_app_type] => utility [patent_app_number] => 17/690437 [patent_app_country] => US [patent_app_date] => 2022-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 18888 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17690437 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18019118 [patent_doc_number] => 20220370617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/652090 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30314 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17652090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657105 [patent_doc_number] => 20220177570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => USE OF THE IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVIATING SYMPTOMS OF PULMONARY SARCOIDOSIS [patent_app_type] => utility [patent_app_number] => 17/675488 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641978 [patent_doc_number] => 20220169716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => PHARMACEUTICAL FORMULATIONS FOR ADALIMUMAB [patent_app_type] => utility [patent_app_number] => 17/673149 [patent_app_country] => US [patent_app_date] => 2022-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18122246 [patent_doc_number] => 20230007847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => PROTEIN FORMULATIONS AND METHODS OF MAKING SAME [patent_app_type] => utility [patent_app_number] => 17/584286 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17584286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704601 [patent_doc_number] => 20220204607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => Production of Biosimilar Ustekinumab In CHO Cells [patent_app_type] => utility [patent_app_number] => 17/572350 [patent_app_country] => US [patent_app_date] => 2022-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 276 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17572350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548101 [patent_doc_number] => 20220119442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => Methods and Devices for the Enrichment of Immunoglobulin from Blood [patent_app_type] => utility [patent_app_number] => 17/564976 [patent_app_country] => US [patent_app_date] => 2021-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17564976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546781 [patent_doc_number] => 20220118122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => STABILIZED RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/563429 [patent_app_country] => US [patent_app_date] => 2021-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17563429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20714196 [patent_doc_number] => 12629420 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-19 [patent_title] => CXCR5 antibody formulations [patent_app_type] => utility [patent_app_number] => 17/562480 [patent_app_country] => US [patent_app_date] => 2021-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 20 [patent_no_of_words] => 15933 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17562480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432591 [patent_doc_number] => 20240301089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => CONDITIONAL CELL CONNECTORS [patent_app_type] => utility [patent_app_number] => 18/269088 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921442 [patent_doc_number] => 20240024446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => CONJUGATED AFLATOXIN B TO PROTECT AGAINST MYCOTOXICOSIS [patent_app_type] => utility [patent_app_number] => 18/257600 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20480364 [patent_doc_number] => 12528835 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Methods for enhanced removal of impurities during protein a chromatography [patent_app_type] => utility [patent_app_number] => 17/554758 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 19771 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17554758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17988910 [patent_doc_number] => 20220354947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSES [patent_app_type] => utility [patent_app_number] => 17/552392 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35527 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938220 [patent_doc_number] => 20240033359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/256578 [patent_app_country] => US [patent_app_date] => 2021-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30639 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480696 [patent_doc_number] => 20220088200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => VISCOSITY REDUCTION OF HIGHLY CONCENTRATED PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/542632 [patent_app_country] => US [patent_app_date] => 2021-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10618 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17905555 [patent_doc_number] => 11459399 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-04 [patent_title] => Pharmaceutical compositions of a HER2/neu antibody and use of the same [patent_app_type] => utility [patent_app_number] => 17/541926 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29437 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480435 [patent_doc_number] => 20220087939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => USE OF AMINO ACIDS AS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/457456 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10250 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17457456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17703341 [patent_doc_number] => 20220203347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => METHOD FOR REGENERATION OF AN OVERLOAD CHROMATOGRAPHY COLUMN [patent_app_type] => utility [patent_app_number] => 17/542138 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542138 [rel_patent_id] =>[rel_patent_doc_number] =>)